MedPath

Reconnect Labs

Reconnect Labs logo
🇨🇭Switzerland
Ownership
Private
Established
2021-01-01
Employees
11
Market Cap
-
Website
https://reconnect-labs.com/

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances

Phase 2
Not yet recruiting
Conditions
Posttraumatic Stress Disorder (PTSD)
Sleep Disturbances and Insomnia
Interventions
Drug: Placebo
First Posted Date
2024-11-13
Last Posted Date
2025-07-09
Lead Sponsor
Reconnect Labs
Target Recruit Count
24
Registration Number
NCT06685965
Locations
🇨🇭

Human Sleep Pharmacology, University of Zurich, Zürich, ZH, Switzerland

Dose-finding PKPD Trial for RE02 in Healthy Subjects

Phase 1
Terminated
Conditions
Healthy
Interventions
First Posted Date
2023-08-07
Last Posted Date
2024-11-27
Lead Sponsor
Reconnect Labs
Target Recruit Count
4
Registration Number
NCT05979727
Locations
🇨🇭

University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland

Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Dimethyltryptamin (DMT) & Harmine
First Posted Date
2023-04-25
Last Posted Date
2023-11-02
Lead Sponsor
Reconnect Labs
Target Recruit Count
16
Registration Number
NCT05829603
Locations
🇨🇭

University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.